Board summary
Key figures
48,180
Registered population
60.4% aged 18–64
18.8%
Aged 65+
ICB 19.9% · England 17.9%
13.1%
Ethnic minority (non-White)
6.3% Asian · England 9.6%
11.2%
In IMD quintile 1
ICB 17.1% · England 21.0%
~4,961
Core20 residents (est.)
Resident basis; registered basis ~5,602 · see page 3
7,990
Hypertension register
+9.41% in 3 yrs · England +5.60%
465
SMI register
27.5% of Maidstone's
916
COPD register
Reviews -15.18% in 3 yrs
Forecast to 2030
10,079
Hypertension patients, 2030
+2,089 on today
71.6%
QRISK ≥20% on statins, 2030
+3.11pp over 3 yrs
4.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD annual reviews fell over three years.
COPD review coverage is 70.6% (England 76.4%) after falling 15.2% from 2023 to 2025 (England +2.8%) as the register grew +8.3%.
Phone access varies sharply across PCN practices.
Ease of phone contact spans from 41.8% at Bower Mount Medical Practice to 87.9% at The Medical Centre Group (20.6% Core20 share).
Under-80 blood pressure and diabetes control lead.
Hypertension control under 80 is 71.6% (England 67.8%), non-frail diabetes HbA1c control is 64.8% (England 57.4%) and QRISK lipid therapy is 64.9%.
Population, age and ethnicity
Patients aged 65 and over number 9,050 alongside 1,369 catchment care home beds
Maidstone Central PCN serves 48,180 registered patients across four practices. Patients aged 65 and over represent 18.8% of the list (9,050 patients), compared with 18.7% in Maidstone, 19.9% in NHS Kent and Medway ICB, and 17.9% in England. Children aged 0 to 17 account for 20.8% (10,035 patients; Maidstone 21.5%, ICB 20.7%, England 19.6%). Census estimates show an ethnic minority population of 13.1%, including 6.3% Asian and 2.6% Black residents, above Maidstone (4.7% Asian, 2.0% Black) and the ICB (4.7%, 3.1%), but below England (9.6%, 4.2%). Registered patients define age; ethnicity reflects Census usual residents.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Maidstone local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Maidstone LA) | 2,653 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.7% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 64.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Maidstone LA) | 1,380 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Maidstone LA) | 15.8 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is moderate at 11.2% and spans 20.6 pp across practices
The PCN Core20 share is 11.2%, below England (21.0%) and NHS Kent and Medway ICB (17.1%) but above Maidstone (9.9%), with an average IMD decile of 6.1. Weighted practice share is 11.6% (a 0.44 percentage point reconciliation difference). Deprivation spans 20.6 pp across practices, concentrated heavily at The Medical Centre Group (20.6%, 3,172 estimated patients) and Brewer Street (19.6%, 1,749 estimated patients), whereas The Vine Medical Centre records 0.0%. Outreach could prioritise these two practices rather than dispersing resources evenly.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
465
SMI register
0.94% recorded prevalence
297
Learning disability register
0.60% recorded prevalence
31
Care homes, 1,369 beds
In the PCN catchment
8.7%
Provide unpaid care
Maidstone, Census 2021
The PCN records 465 patients on its severe mental illness register (0.9%, England 1.0%) and 297 on its learning disability register (0.6%, matching England). The catchment also contains 1,369 care home beds across 31 sites, though bed counts do not establish resident registration.
Severe mental illness: physical health checks
From 2023 to 2025, SMI blood pressure checks fell 3.0 pp (England +4.4 pp) to 82.7% (England 83.4%), with Bower Mount Medical Practice recording 75.0% and The Vine Medical Centre 79.8%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,990
Hypertension register
+9.41%
Register growth, 3 yrs
Maidstone +4.31% · England +5.60%
+3.95pp
BP control, under 80
≤140/90 · −0.94pp aged 80+
+2,089
More patients by 2030
Forecast 10,079 (19.40%)
Hypertension case-finding and control
The hypertension register records 7,990 patients (16.2% prevalence). From 2023 to 2025, prevalence grew +9.4% (+1.4 pp; England +5.6%, +0.8 pp; Maidstone +4.3%). Blood pressure control under age 80 reached 71.6% (England 67.8%, Maidstone 66.6%), though Bower Mount Medical Practice recorded 61.5%. For patients aged 80 and over, control fell 0.9 pp (England +1.8 pp) to 79.4% (England 81.2%, Maidstone 77.9%), dropping 1.2% (England +2.2%). Current observation periods were not captured.
Lipids and statins
For patients with QRISK ≥ 20%, 64.9% receive lipid-lowering therapy (England 63.6%, Maidstone 60.3%). However, adult prescribing of lipid-regulating drugs in 2026 was 2,151 items per 1,000, trailing England (4,100 rate). This gap may reflect differing prescribing intervals or case-mix; a local prescribing audit would test it.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 82,033 | £1.50 | £1.90 | £1.86 | £123,050 |
| Cardiovascular (all), 2025 | 101,113 | £3.40 | £3.57 | £3.33 | £343,784 |
In 2026, the PCN prescribed 82,033 items for lipid-regulating drugs at £1.50 per item (England £1.86, Maidstone £1.62, NHS Kent and Medway ICB £1.90). Across these items, the PCN spent £29,532 less than at England's unit cost. This unit-cost difference does not evaluate clinical appropriateness or efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.88%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.48%
Asthma prevalence, PCN 3-yr % change
From 2023 to 2025, the COPD register grew +8.3% to 916 patients (1.9% prevalence, matching England), yet annual reviews fell 15.2% (England +2.8%) to 70.6% (England 76.4%). Across the 2,790-patient asthma register, reviews fell 2.9% (England +4.4%) to 66.1%, leaving about 950 patients unreviewed, with Brewer Street at 52.9%. Falling review rates alongside register growth may reflect capacity pressure; a clinical recall audit would test it.
Cancer register and children's immunisation
Cancer prevalence is 4.0% (1,981 patients; England 3.8%). Childhood immunisation shows strong early uptake, with MMR dose 1 at 24 months reaching 97.8% (England 88.3%). However, pre-school coverage at age 5 drops to 89.0% for MMR dose 2 and 87.4% for 4-in-1, below the 95% target by 6 pp and 7.6 pp, with The Vine Medical Centre recording 78.6% for MMR2. Pre-school booster recall is the main paediatric priority.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of staged cancers (4,661 of 8,384) across NHS Kent and Medway ICB were diagnosed at stage 1 or 2, above England (55.3%) but 19.4 pp below the 75.0% national ambition for 2028. Staging was known for 63.6% of registered cancers (8,384 of 13,189; England 67.0%), leaving an ICB scale gap of 1,627 early-stage cases. Staging data is ICB-level, not PCN performance. PCN cervical screening coverage is 71.8% (England 66.8%) but fell 1.8% from 2023 to 2025 (England -1.0%), with The Vine Medical Centre at 64.0%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data, Maidstone and Tunbridge Wells NHS Trust achieved 87.4% on the 62-day cancer standard (England 71.2%, ICB 75.9%, Medway NHS Foundation Trust 81.6%, Dartford and Gravesham NHS Trust 63.6%). The trust reached 81.8% on the 28-day faster diagnosis standard (England 79.3%). For all diagnostic tests, 6.4% waited six weeks or more (England 23.1%). However, 19.8% for colonoscopy and 28.2% for flexi sigmoidoscopy waited six or more weeks (Medway 1.9% and 3.8%; Dartford 0.4% and 0.0%). These figures reflect provider activity rather than PCN performance.
| Pathways within standard (%) | Maidstone and Tunbridge Wells | Medway | Dartford and Gravesham | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.78 | 77.77 | 78.14 | 76.78 | 79.32 |
| 31-day treatment (96%) | 98.35 | 99.62 | 97.48 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 87.43 | 81.64 | 63.59 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Maidstone and Tunbridge Wells | Medway | Dartford and Gravesham | England |
|---|---|---|---|---|
| MRI | 0.92 | 0.68 | 0.36 | 21.40 |
| CT | 0.51 | 0.00 | 2.08 | 9.92 |
| Echocardiography | 2.57 | 36.62 | 3.90 | 28.48 |
| Colonoscopy | 19.80 | 1.88 | 0.40 | 30.83 |
| Gastroscopy | 24.03 | 3.32 | 0.00 | 29.02 |
| All 15 DM01 tests | 6.42 | 14.20 | 8.37 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In provisional June 2026 data, 65.8% of community service contacts for Maidstone borough residents (138,250 of 210,170 contacts) were with adults aged 65 and over. These figures reflect borough resident utilisation rather than PCN delivery.
Practice variation and patient experience
Patient experience spans 28.9 percentage points across practices, contrasting with local deprivation
In 2025/26, overall QOF achievement exceeded England (92.5%) across all four practices, led by The Medical Centre Group at 99.4%. Vaccination and immunisation achievement showed a 57.7 pp range, from 37.3% at Brewer Street to 95.0% at The Medical Centre Group. Personalised care adjustments reached 11.6% at The Vine Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Group | 98 | 20.6 | 87.9% | 82.4% | 90.4% |
| Brewer Street | 124 | 19.6 | 78.0% | 60.8% | 86.0% |
| Bower Mount | 113 | 6.3 | 41.8% | 68.1% | 77.4% |
| Vine | 116 | 0.0 | 52.9% | 72.5% | 61.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Routine reviews fell while depression grew 19.9% and dementia grew 17.4%
Across 25 tracked measures, 15 trail England's three-year change. Routine care contracted in COPD reviews (fell 15.2%, England +2.8%), SMI blood pressure checks (down 3.0 pp, England +4.4 pp), and asthma reviews (down 2.9%, England +4.4%). Meanwhile, registers for depression grew +19.9% and dementia grew +17.4%. Conversely, non-frail diabetes HbA1c control rose +6.5% (England +4.4%) and blood pressure control under age 80 rose +5.8% (England +3.2%). Rapid register growth may be compressing routine review capacity.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
BP check (SMI)
Asthma reviews
Heart failure reviews
BMI record (SMI)
Diabetes statin (no CVD)
BP control, under 80
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Maidstone | Asset | PCN | Maidstone |
|---|---|---|---|---|---|
| Care homes (catchment) | 31 (1,369 beds) | n/a | Schools (catchment) | 87 | n/a |
| Children's centres | 6 | 7 | Places of worship | 49 | 94 |
| Libraries | 4 | 9 | Food banks (VCS) | 1 | 1 |
| Homelessness support (VCS) | 1 | 1 | Day centres (VCS) | 3 | 3 |
| Children and young people (VCS) | 3 | 3 | Carers support groups (VCS) | 3 | 4 |
| Primary schools (LA maintained) | 10 | 28 | Primary academies | 12 | 14 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Respiratory annual review recall audit
Asthma reviews are 66.1% across 2,790 patients (about 950 unreviewed; Brewer Street 52.9%) after falling 2.9% (England +4.4%). COPD reviews are 70.6% across 916 patients (England 76.4%) after falling 15.2% (England +2.8%). For discussion: run a structured respiratory recall and template review, starting with practices with lower review rates. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
SMI physical health check outreach
Across 465 SMI patients, annual blood pressure checks fell 3.0 pp from 2023 to 2025 (England +4.4 pp) to 82.7% (England 83.4%), with Bower Mount Medical Practice at 75.0% and The Vine Medical Centre at 79.8%. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Older-age CVD and lipid audit
BP control at age 80+ is 79.4% (England 81.2%) after falling 1.2% (England +2.2%). Heart failure prevalence is 0.9% (458 patients; England 1.1%, gap range -18 to +71), and adult lipid prescribing is 2,151 per 1,000 (England 4,100). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Care home clinical capacity review (p2) | Count of care home beds in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Older age hypertension recall audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice access and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Respiratory annual review recall audit (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · SMI physical health check outreach (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Older-age CVD and lipid audit (p12) | Hypertension register · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) · Heart failure register | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
